BCL2L1 and glioblastoma: Researchers have designed acid-sensitive bionic nanocarriers based on ApoE peptide-modified erythrocyte membranes for the delivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors to treat glioblastoma (GBM).